Cadrenal Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Cadrenal Therapeutics, Inc. (CVKD) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $672.10 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $672.10K, a 37.40% increase year-over-year.
- Cadrenal Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $252.36K, a 51.36% decline year-over-year.
- Cadrenal Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $325.10K, a 66.23% increase year-over-year.
- Cadrenal Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $473.38K, a 142.04% increase year-over-year.
- Cadrenal Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $1.81M, a 141.84% increase from fiscal 2024.
- Cadrenal Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $747.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $672.10K 10-Q · filed 2026-08-13 | $924.47K 10-Q · filed 2026-08-13 | $1.25M derived: sum of 3 quarters · filed 2026-08-13 | $1.72M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $252.36K 10-Q · filed 2026-05-07 | $577.47K derived: sum of 2 quarters · filed 2026-05-07 | $1.05M derived: sum of 3 quarters · filed 2026-05-07 | $1.54M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $325.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $798.49K derived: sum of 2 quarters · filed 2026-03-31 | $1.29M derived: sum of 3 quarters · filed 2026-08-13 | $1.81M 10-K · filed 2026-03-31 |
| 2025-09-30 | $473.38K 10-Q · filed 2025-11-10 | $962.53K derived: sum of 2 quarters · filed 2026-08-13 | $1.48M 10-Q · filed 2025-11-10 | $1.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $489.14K 10-Q · filed 2026-08-13 | $1.01M 10-Q · filed 2026-08-13 | $1.20M derived: sum of 3 quarters · filed 2026-08-13 | $1.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $518.89K 10-Q · filed 2026-05-07 | $714.46K derived: sum of 2 quarters · filed 2026-05-07 | $910.04K derived: sum of 3 quarters · filed 2026-05-07 | $1.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $195.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $391.15K derived: sum of 2 quarters · filed 2026-03-31 | $584.27K derived: sum of 3 quarters · filed 2026-03-31 | $747.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $195.58K 10-Q · filed 2025-11-10 | $388.70K derived: sum of 2 quarters · filed 2025-11-10 | $551.43K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $193.12K 10-Q · filed 2025-08-11 | $355.85K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $162.73K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |